Sandy Calero

Manager Accounting at The Medicines Co.

Sandy Calero

Sandy Calero

Manager Accounting at The Medicines Co.

Overview
RelSci Relationships

155

Contact Data
Trying to get in touch with Sandy Calero? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Sandy Calero likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chief Medical Officer at Immunomedics Inc.

Relationship likelihood: Weak

Former Chief Human Strategy Officer at The Medicines Co.

Relationship likelihood: Weak

Senior Vice President & Chief Financial Officer at Agile Therapeutics, Inc.

Relationship likelihood: Weak

Managing Partner at Amzak Capital Management LLC

Relationship likelihood: Weak

Co-Founder at JSB-Partners LP

Relationship likelihood: Weak

Former Chief Executive Officer at Curacyte AG

Relationship likelihood: Weak

Vice President-Finance, Principal Accounting Officer at Panacos Pharmaceuticals, Inc.

Relationship likelihood: Weak

Former Chief Human Strategy Officer & Executive Vice President at The Medicines Co.

Relationship likelihood: Weak

Chief Medical Officer (CMO) at Amryt Pharma PLC

Relationship likelihood: Weak

Chief Medical Officer at Intercept Pharmaceuticals, Inc.

Relationship likelihood: Weak

Paths to Sandy Calero
Potential Connections via
Relationship Science
You
Sandy Calero
Manager Accounting at The Medicines Co.
Career History
Manager Accounting
Tenure Unconfirmed

The Medicines Co We are a global pharmaceutical company focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. In the United States, we have three marketed products, Angiomax® (bivalirudin) for Injection, Cleviprex® (clevidipine) Injectable Emulsion, and Argatroban Injection, 50 mg per 50 mL†. We also have a pipeline of acute and intensive care hospital products in development, including three late-stage development product candidates, cangrelor, oritavancin and MDCO-157, and two early stage development product candidates, MDCO-2010 and MDCO-216. We believe that Angiomax, Cleviprex and our products in development possess favorable attributes that can satisfy unmet medical needs in the acute | intensive care hospital product market and offer, or, in the case of our products in development, have the potential to offer, improved performance to hospital businesses. The Company is publicly traded on the Nasdaq exchange under the ticker symbol MDCO. It was founded in 1996 and employs approximately 425 professionals.

Other Affiliations

Sandy Calero is affiliated with The Medicines Co.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Sandy Calero. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Sandy Calero's profile does not indicate a business or promotional relationship of any kind between RelSci and Sandy Calero.